J Korean Assoc Oral Maxillofac Surg 2019; 45(1): 3~8
Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology
Antonio Fabrizio Nifosì1, Mariateresa Zuccarello2, Lorenzo Nifosì3, Vanessa Hervas Saus4, Gianfilippo Nifosì5
1Dental Surgeon, Forlì, 2Department of Medicine, University of Catania, Catania, Italy,
Departments of 3Dentistry and 4Dental Hygiene, European University of Valencia, Valencia, Spain,
5Hemato-Oncology Clinic, Department of Internal Medicine, Brugmann University Hospital Center, Brussels, Belgium
Gianfilippo Nifosì
Hemato-Oncology Clinic, Department of Internal Medicine, Brugmann University Hospital Center, 4 Van Gehuchten Square, 1082 Brussels, Belgium
TEL: +32-2-477-31-65 FAX: +32-477-35-29
E-mail: g.nifosi @tin.it
ORCID: https://orcid.org/0000-0003-4329-6297
Received March 11, 2018; Revised May 24, 2018; Accepted May 27, 2018.; Published online February 28, 2019.
© The Korean Association of Oral and Maxillofacial Surgeons.. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Osteonecrosis of the jaw (ONJ) is a well-known pathological condition in oncology derived from the use of bisphosphonates (BPs) and denosumab. Many molecular and immunological targets have been introduced for daily use in cancer treatment in recent years; consequently, new cases of ONJ have been reported in association with these drugs, especially if administered with BPs and denosumab. When the drugs are administered alone, ONJ is rarely seen. The objective of our study was to analyze the recent literature relative to the association of ONJ with these new drugs highlighting the pathogenic, clinical and therapeutic aspects. The close collaboration between maxillofacial surgeon, oncologist, dentist, and dental hygienist remains the most important aspect for the prevention, prompt recognition, and treatment of this pathology.
Keywords: Bone, Infection, Oral manifestations, Immunomodulation, Angiogenesis modulators

Current Issue

30 June 2019
Vol. 45
No. 3 pp. 121~172

Indexed in